- Home
- NXTC
NXTC
NextCure Inc.
as 12-18-2024 2:40pm EST
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | BELTSVILLE |
| Market Cap: | 31.6M | IPO Year: | 2019 |
| Target Price: | $4.00 | AVG Volume (30 days): | 204.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.89 - $2.57 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest NextCure Inc. News
NXTC Breaking Stock News: Dive into NXTC Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
NextCure Announces Acceptance of IND Application for LNCB74
GlobeNewswire
22 days ago
NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference
GlobeNewswire
a month ago
Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta
GlobeNewswire
a month ago
NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results
GlobeNewswire
a month ago
NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting
GlobeNewswire
2 months ago
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting
GlobeNewswire
3 months ago
NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024
Simply Wall St.
3 months ago
Is NextCure (NASDAQ:NXTC) In A Good Position To Deliver On Growth Plans?
Compare NXTC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NXTC NextCure Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.